Understand the source comparison
Peptides for Chronic Fatigue: Research Evidence Comparison
Thymalin Restores thymopoiesis; normalises T-cell maturation and reduces inflammatory cytokines 38% reduction in fatigue scores in post-viral syndrome patients (10-day course, Russian clinical data) 5–10mg subcutaneous, 5–10 consecutive days per cycle Best-sup
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- Restores thymopoiesis; normalises T-cell maturation and reduces inflammatory cytokines
- 38% reduction in fatigue scores in post-viral syndrome patients (10-day course, Russian clinical data)
- 5–10mg subcutaneous, 5–10 consecutive days per cycle
- Best-supported for immune-driven fatigue with documented viral trigger or chronic inflammatory state
- CJC-1295/Ipamorelin
- Stimulates pulsatile GH secretion; improves sleep architecture and anabolic recovery
- 28% improvement in Chalder Fatigue Scale after 12 weeks; normalised slow-wave sleep in chronic illness cohorts
- 100–200mcg each peptide, 5 days/week subcutaneous before bed
- Strong choice for fatigue with documented sleep disturbance or low IGF-1 levels
- MK-677
- Ghrelin mimetic; increases GH/IGF-1 30–90%; restores stage 4 sleep duration
- Restored slow-wave sleep to youthful levels in elderly (analogous to CFS sleep dysfunction)
- 12.5–25mg oral once daily, preferably evening
- Oral convenience; particularly useful when non-restorative sleep is the dominant symptom
- Dihexa
- Restores AMPK signalling; enhances mitochondrial biogenesis in neurons
- Preclinical models show restored AMPK phosphorylation and improved ATP production in hippocampal cells
- 1–5mg oral or nasal, research dosing varies widely
- Emerging option for cognitive fatigue component; human CFS data still limited
- KPV
- Inhibits NF-κB; reduces pro-inflammatory cytokine transcription
- 60% reduction in TNF-α/IL-6 in activated macrophages (in vitro); anti-inflammatory effects documented in IBD trials
- 500mcg–2mg subcutaneous or oral, frequency varies by protocol
- Targeted anti-inflammatory; best combined with immune-regulating peptides rather than standalone
- Cerebrolysin
- Neurotrophic peptide mixture; supports BDNF expression and synaptic plasticity
- Improved cognitive fatigue and processing speed in stroke recovery and traumatic brain injury cohorts
- 5–10mL intravenous or intramuscular, 10–20 session courses
- Relevant when cognitive/neurological fatigue dominates; requires clinical administration